Gascón, Pere
Awada, Ahmad
Karihtala, Peeter
Lorenzen, Sylvie
Minichsdorfer, Christoph http://orcid.org/0000-0002-5455-9139
Funding for this research was provided by:
Sandoz International GmbH
Medical University of Vienna
Article History
Received: 15 September 2023
Accepted: 9 October 2023
First Online: 27 November 2023
Conflict of interest
: P. Gascón is Editor-in-Chief of <i>Clinical and Translational Oncology</i>. A. Awada has acted in an advisory role for Amgen, AstraZeneca, Bayer, Daiichi, Eisai, Genomic Health, Hengrui, Innate, Ipsen, LEO Pharma, Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics, and has received speaker fees for Amgen, AstraZeneca, Bayer, Daiichi, Eisai, Genomic Health, Ipsen, LEO Pharma, Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics; his institute has received research grants from Bristol Myers Squibb and Roche. P. Karihtala has received honoraria from Amgen and Sandoz. C. Minichsdorfer has received honoraria from Sandoz, Boehringer Ingelheim, MSD, and Amgen, as well as travel grants from MSD and Merck Darmstadt. S. Lorenzen declares that she has no competing interests.